New OLE Data: Spesolimab Reduces GPP Flare Frequency

Spesolimab-sbzo (Spevigo, LEO Pharma) slashed flare frequency in patients with generalized pustular psoriasis (GPP), with nearly 75% of patients reporting no flares over three years, according to new long-term results from EFFISAYIL ON, an ongoing five-year open-label extension study of the pivotal EFFISAYIL 1 trial and the EFFISAYIL 2 trials.